Dimitrios Bouzianas
Research Subjects
Research Interests
Dimitrios Bouzianas has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Stella Bouziana
King's College Hospital NHS Foundation Trust London UK
5 shared publications - Apostolos I. Hatzitolios
First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
1 shared publication Stella D Bouziana
First Propedeutic Department of Internal Medicine; Medical School; AHEPA University Hospital; Aristotle University of Thessaloniki; Thessaloniki Macedonia Greece
1 shared publication
Latest Publications
- 2 January 2026
- Published by Cassyni
Optimization of CAR T-cell dose: a debated unresolved issue
CAR T-cell therapies are incredibly potent in killing tumour cells and have been extremely successful in putting hematologic patients into remission. However, there are still multiple challenges such as life-threatening toxicities and high relapse rates. Balancing the anti-tumor efficacy while sparing detrimental toxicities would be the desirable outcome. CAR T-cells behave as “living multi-drugs” because each cell type has its own kinetic and dynamic parameters. Therefore, the kinetics and function of a CAR T-cell product is unpredictable and variable. Optimising the CAR T-cell dose in terms of cell numbers and subpopulations, is extremely challenging as multiple factors seem to have an impact on CAR T-cell function, while published clinical trials have used a wide range of cell doses rendering the comparison of outcomes elusive. We propose a research model for determining the optimal therapeutic dose in CAR T-cell personalized therapies. We believe that both toxicity and relapse do not seem to be with the cellular products, per se, but rather with the followed therapeutic strategy. Scientists should turn backwards 180° degrees and take the reverse research direction to find the underlying root causes. The disconnection of the CAR-T product efficacy from long-term persistence is set as a prerequisite. Developing a model that identifies root causes of adverse events could lead to personalized therapies with optimized dosing and reduced side effects. Such advancements could facilitate outpatient treatment administration, reduce healthcare costs, and increase patient access to CAR T-cell therapies.
- 2 January 2026
- Published by Cassyni
Optimization of CAR T-cell dose: a debated unresolved issue
CAR T-cell therapies are incredibly potent in killing tumour cells and have been extremely successful in putting hematologic patients into remission. However, there are still multiple challenges such as life-threatening toxicities and high relapse rates. Balancing the anti-tumor efficacy while sparing detrimental toxicities would be the desirable outcome. CAR T-cells behave as “living multi-drugs” because each cell type has its own kinetic and dynamic parameters. Therefore, the kinetics and function of a CAR T-cell product is unpredictable and variable. Optimising the CAR T-cell dose in terms of cell numbers and subpopulations, is extremely challenging as multiple factors seem to have an impact on CAR T-cell function, while published clinical trials have used a wide range of cell doses rendering the comparison of outcomes elusive. We propose a research model for determining the optimal therapeutic dose in CAR T-cell personalized therapies. We believe that both toxicity and relapse do not seem to be with the cellular products, per se, but rather with the followed therapeutic strategy. Scientists should turn backwards 180° degrees and take the reverse research direction to find the underlying root causes. The disconnection of the CAR-T product efficacy from long-term persistence is set as a prerequisite. Developing a model that identifies root causes of adverse events could lead to personalized therapies with optimized dosing and reduced side effects. Such advancements could facilitate outpatient treatment administration, reduce healthcare costs, and increase patient access to CAR T-cell therapies.
- 19 June 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (9) , 1286-1288
Optimization of CAR T-cell dose: a debated unresolved issue
- 19 June 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (9) , 1286-1288
Optimization of CAR T-cell dose: a debated unresolved issue
- Open Access
- 1 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9518
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.
- 1 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9518
Open AccessThe Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.
- Open Access
- 26 June 2024
- Published by IntechOpen
Autologous Adipose Tissue Stem Cell-Derived Terminally Differentiated Retinal Pigment Epithelium Monolayer on a Biocompatible Scaffold, to Restore Vision in Age-Related Macular Degeneration Patients
In Western countries, age-related macular degeneration (AMD) is the common cause of central visual loss in the elderly leading to gradual blindness. Studies implicate the retinal pigment epithelium (RPE) as an important player in AMD pathogenesis, as progressive loss of RPE cells and photoreceptors lead to poor visual acuity. Several strategies aim to prevent the RPE degeneration by saving the damaged retinal cells or replacing them. Cell rescue provides retinal cells with trophic or immunomodulatory factors, whereas cell replacement aims to repair and regenerate neuroretina providing new cells. Currently, a major limitation is cell loss from subretinal injections of bolus cell suspensions. The most promising studies focus on tissue transplantation or RPE cell patches hosted on implantable scaffolds made of advanced biomaterials. The latter support the development of artificial 3D retinal constructs improving functional integration capacity and increasing the survival of implanted cells into the damaged retina. However, there is no consensus on the optimal RPE source, delivery strategy, cell dose and animal model for testing. This chapter aims to improve the efficacy of RPE grafting suggesting an optimal cell source, an efficient delivery method, and the topography of retina damage as a determining factor to calculate the effective therapeutic dose.
- 26 June 2024
- Published by IntechOpen
Open AccessAutologous Adipose Tissue Stem Cell-Derived Terminally Differentiated Retinal Pigment Epithelium Monolayer on a Biocompatible Scaffold, to Restore Vision in Age-Related Macular Degeneration Patients
In Western countries, age-related macular degeneration (AMD) is the common cause of central visual loss in the elderly leading to gradual blindness. Studies implicate the retinal pigment epithelium (RPE) as an important player in AMD pathogenesis, as progressive loss of RPE cells and photoreceptors lead to poor visual acuity. Several strategies aim to prevent the RPE degeneration by saving the damaged retinal cells or replacing them. Cell rescue provides retinal cells with trophic or immunomodulatory factors, whereas cell replacement aims to repair and regenerate neuroretina providing new cells. Currently, a major limitation is cell loss from subretinal injections of bolus cell suspensions. The most promising studies focus on tissue transplantation or RPE cell patches hosted on implantable scaffolds made of advanced biomaterials. The latter support the development of artificial 3D retinal constructs improving functional integration capacity and increasing the survival of implanted cells into the damaged retina. However, there is no consensus on the optimal RPE source, delivery strategy, cell dose and animal model for testing. This chapter aims to improve the efficacy of RPE grafting suggesting an optimal cell source, an efficient delivery method, and the topography of retina damage as a determining factor to calculate the effective therapeutic dose.
- Open Access
- 25 February 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2321678
First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?
- 25 February 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2321678
Open AccessFirst pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?
- Open Access
- 31 October 2023
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (5) , 1128-1135
A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin
- 31 October 2023
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (5) , 1128-1135
Open AccessA decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin
- 15 October 2013
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 71 (11) , 753-771
Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the Western world. Its prevalence has increased with the growin
- 15 October 2013
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 71 (11) , 753-771
Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the Western world. Its prevalence has increased with the growin